|
||||||||||
|
| Investor Relations | News | |||||
|
BiondVax Pharmaceuticals (TASE:BNDK) is developing a revolutionary vaccination that will provide universal multi-season/multi-strain protection against most human influenza virus strains, as well as the Avian flu. The Flu vaccine industry, estimated currently at $2 Billion, is expected to grow to a $4 Billion market by 2012. Between 250 and 300 million doses are currently administered annually worldwide.
Since its inception in 2003, the company has raised $8.5 million to date. This includes $4.5 million from private investors, $1 million from the Israeli Office of the Chief Scientist (OCS), a government scientific investment authority, and most recentlyan additional $3 million from its IPO on the Tel Aviv Stock Exchange, completed in June 2007. The IPO included an issue of 3.53 million stocks and 350,000 stock options with a striking price of 3.47 NIS ($ 0.838 USD). Stock Information: Stock Symbol: TASE: BNDK Corporate Profile http://www.tase.co.il/ Stock Chart http://www.tase.co.il/companyGraph.htm Stock historical prices http://www.tase.co.il/companyHistoryData.htm |
|||||
|
